Stock AnalizCogent Biosciences, Inc. COGT
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Cogent Biosciences, Inc. (COGT) is a healthcare company listed in the US with a market value of about $5.0B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -48%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $8M | $22M | $10M | $8M |
| Net income | -$329M | -$256M | -$192M | -$140M | -$72M | -$75M | -$32M | -$35M | -$25M |
| Free cash flow | -$266M | -$208M | -$156M | -$126M | -$60M | — | -$42M | -$33M | -$27M |
| EPS (diluted) | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 | $-16.17 | $-4.18 | $-5.56 | $-10.04 |
| Net margin | — | — | — | — | — | -950.4% | -141.5% | -354.8% | -304.9% |
| ROIC | -30.1% | -79.6% | -59.4% | -42.4% | -27.5% | -27.1% | -67.3% | -47.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $55.82, 95% above the current price; targets range from $45.00 to $61.00; the consensus rating is “Strong buy”; expected EPS is $-2.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Cogent Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cogent Biosciences pay a dividend?
Not currently.
Is Cogent Biosciences a good stock to buy?
We do not give buy or sell advice. Cogent Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.